Coronary CT Angiogram: What 'Normal' Really Means vs. Functional Optimal

What a Coronary CT Angiogram Actually Shows

A coronary CT angiogram produces high-resolution 3D images of your coronary arteries using contrast-enhanced CT scanning. Unlike a standard calcium score scan, CCTA visualizes both calcified and non-calcified (soft) plaque, measures the degree of arterial narrowing, and characterizes plaque composition.

The test generates several distinct data points: a coronary artery calcium (CAC) score quantified by the Agatston method, a stenosis percentage for each coronary segment, plaque composition analysis (calcified, partially calcified, or non-calcified), and an overall CAD-RADS classification that standardizes reporting across institutions [1]. The 2021 ACC/AHA Chest Pain Guidelines elevated CCTA to a Class 1 recommendation for evaluating stable chest pain in intermediate-risk patients, reflecting strong evidence that anatomical imaging changes clinical outcomes [2]. In the SCOT-HEART trial (N=4,146), CCTA-guided management cut the rate of coronary heart disease death or nonfatal myocardial infarction from 3.9% to 2.3% over 5 years, a 41% relative reduction [3]. That benefit came primarily from reclassifying patients who appeared low-risk by stress testing alone but harbored significant plaque on imaging.

The CAD-RADS Reporting System: Where "Normal" Gets Defined

The Coronary Artery Disease Reporting and Data System (CAD-RADS) provides a standardized 0-5 scale that your radiologist or cardiologist uses to communicate CCTA findings. The 2022 CAD-RADS 2.0 update refined the original 2016 framework to include plaque burden modifiers and ischemia assessment [4].

Here is how the scale breaks down:

• CAD-RADS 0: No plaque or stenosis. Zero atherosclerosis detected.
• CAD-RADS 1: Minimal stenosis (1-24%). Plaque present but not flow-limiting.
• CAD-RADS 2: Mild stenosis (25-49%). Non-obstructive disease.
• CAD-RADS 3: Moderate stenosis (50-69%). Possible functional significance.
• CAD-RADS 4: Severe stenosis. 4A is 70-99% in one or two vessels. 4B is left main >50% or three-vessel disease >70%.
• CAD-RADS 5: Total coronary occlusion.

Standard clinical practice considers both CAD-RADS 0 and CAD-RADS 1 as "normal" or "no significant disease." This is where the gap between clinical normal and functional optimal opens. A CAD-RADS 1 report means plaque exists. The artery is not clean. That distinction matters.

What "Normal" Misses: The CAD-RADS 1 Problem

A patient receiving a CAD-RADS 1 result often hears "your scan is normal" from their clinician. That framing, while technically correct by reporting standards, obscures an important reality: atherosclerosis has begun.

Data from the CONFIRM registry (N=27,125) demonstrated that patients with non-obstructive coronary artery disease (CAD-RADS 1-2) had significantly higher mortality than patients with truly clean arteries (CAD-RADS 0) [5]. The hazard ratio for all-cause mortality in patients with non-obstructive CAD was 1.60 compared to those with no detectable disease. This was not a marginal difference. Patients told their scans were "normal" carried 60% higher mortality risk than those with genuinely clear coronaries.

Dr. Leslee Shaw, a cardiovascular imaging researcher at Weill Cornell Medicine, has noted: "Non-obstructive coronary disease is not benign. These patients need aggressive risk factor modification, not reassurance." [5]

The practical consequence: if your CCTA report says CAD-RADS 1, you have early coronary atherosclerosis. Preventive therapy (statin initiation, blood pressure optimization, lifestyle modification) should be on the table, not a follow-up scan in five years.

Coronary Artery Calcium Score: The Quantitative Backbone

The CAC score, measured in Agatston units, provides the most granular numeric output from cardiac CT imaging. While CCTA includes both calcified and non-calcified plaque visualization, the CAC score specifically quantifies calcified plaque burden. The Multi-Ethnic Study of Atherosclerosis (MESA) established population-based percentiles stratified by age, sex, and ethnicity [6].

Standard clinical thresholds classify CAC scores as follows:

• 0: No identifiable calcified plaque
• 1-99: Mild calcified plaque
• 100-299: Moderate calcified plaque
• 300-999: Severe calcified plaque
• 1,000+: Very severe calcified plaque

A CAC score of 0 is the only functionally optimal result. Even a score of 1-10 places a patient into a different risk category. In MESA follow-up data, participants with CAC scores of 1-100 had a 3.89-fold higher rate of coronary events compared to those with a CAC of 0 over 10 years of follow-up [6]. The 2019 ACC/AHA Primary Prevention Guidelines specifically endorse CAC scoring as a tie-breaker for statin therapy decisions in borderline-risk patients (5-7.5% ten-year ASCVD risk), recommending treatment initiation when CAC is >0 [7].

A CAC of 0 does not guarantee the absence of all plaque. Non-calcified, lipid-rich plaques can exist without any calcium signal. This is precisely why full CCTA (which detects soft plaque) provides more complete information than a standalone calcium score.

Functional Optimal: The Clean-Artery Standard

Functional optimal on coronary CT angiography means all of the following are true simultaneously:

1. CAC score = 0 (no calcified plaque detected by Agatston method)
2. No non-calcified plaque visible on contrast-enhanced images
3. CAD-RADS 0 classification (no stenosis in any segment)
4. No high-risk plaque features (no positive remodeling, low-attenuation plaque, napkin-ring sign, or spotty calcification)

This represents a coronary vasculature free of detectable atherosclerotic disease. Among adults over 50, this finding is surprisingly uncommon. MESA data showed that approximately 50% of men aged 45-54 and 16% of women in the same age range already have a CAC score above 0 [6]. By age 65-74, those figures climb to 80% for men and 52% for women.

The clinical value of confirming a truly optimal result is significant. A 2017 analysis published in JACC found that a CAC score of 0 conferred a 10-year coronary event rate below 1.5% regardless of the number of traditional risk factors present [8]. This "warranty period," as researchers have termed it, allows confident de-escalation of pharmacotherapy in selected patients. If your ten-year ASCVD risk estimate suggests borderline eligibility for a statin but your CAC is 0 and CCTA shows no plaque, current guidelines support deferring medication and rechecking in 5-10 years.

High-Risk Plaque Features: What Standard Reporting May Underemphasize

Beyond stenosis percentage and calcium score, CCTA can identify specific plaque characteristics that predict acute coronary events. Motoyama et al. identified three high-risk features on CCTA that predicted acute coronary syndrome with a hazard ratio of 22.8 over a mean 27-month follow-up [9]:

• Positive remodeling: The arterial wall expands outward to accommodate plaque, masking the true plaque burden on standard angiography
• Low-attenuation plaque (<30 Hounsfield units): Indicates a large lipid-necrotic core, the substrate for plaque rupture
• Spotty calcification: Small, punctate calcium deposits within a predominantly soft plaque, distinct from the dense, stable calcification measured by the Agatston score

A report that reads "no significant stenosis" may contain all three of these features. The stenosis is <50%, so it falls into the "non-obstructive" category, yet the plaque morphology carries high rupture risk. This is why a truly optimal interpretation requires more than a glance at the CAD-RADS number. Ask your clinician whether the report comments on plaque composition and high-risk features, not only stenosis severity.

The 2022 CAD-RADS 2.0 update addressed this gap by adding a plaque burden modifier (P1-P4) that captures total atherosclerotic volume independent of stenosis percentage [4]. A patient could be classified as CAD-RADS 1/P3 (minimal stenosis but high plaque burden), a result that looks "normal" by the old system but signals aggressive preventive intervention under the updated framework.

How to Improve Your Coronary CT Angiogram Findings

You cannot reverse calcified plaque once it has formed. A CAC score of 150 will not drop to 0. Calcification is permanent. What you can do is slow or halt plaque progression and stabilize existing plaques so they are less likely to rupture.

The evidence base for slowing CAC progression centers on statin therapy. In the St. Francis Heart Study, atorvastatin 20 mg daily reduced coronary events by 42% in patients with CAC scores above 400, though it did not reduce CAC progression itself [10]. Statins stabilize plaque composition (shifting from lipid-rich to fibrous/calcified morphology) rather than shrinking total calcium volume.

Interventions supported by evidence for slowing plaque progression include:

• Statin therapy: LDL-C targets of <70 mg/dL for patients with documented non-obstructive CAD per 2018 ACC/AHA cholesterol guidelines [11]
• Blood pressure control: Target <130/80 mmHg per 2017 ACC/AHA hypertension guidelines
• Smoking cessation: The single largest modifiable risk factor for plaque progression
• GLP-1 receptor agonists: The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease and overweight/obesity, independent of diabetes status [12]
• PCSK9 inhibitors: For patients not reaching LDL targets on maximally tolerated statins, the GLAGOV trial showed evolocumab reduced plaque volume by 0.95% over 76 weeks [13]

A repeat CCTA at 3-5 year intervals can track whether new non-calcified plaque has appeared, whether existing plaques have stabilized, or whether stenosis has progressed. Serial CAC scoring (without contrast) at 5-year intervals is a lower-radiation alternative for monitoring calcified plaque trajectory.

When Your Clinician Should Order a CCTA

Not everyone needs a coronary CT angiogram. The test involves iodinated contrast, radiation exposure (1-5 mSv on modern scanners), and costs between $300 and $1,500 depending on insurance and facility.

The 2021 ACC/AHA Chest Pain Guidelines recommend CCTA as a first-line test for:

• Stable chest pain in patients with intermediate pre-test probability of obstructive CAD (Class 1 recommendation) [2]
• Acute chest pain in emergency department patients with low-to-intermediate risk (as an alternative to stress testing)
• Evaluation of new-onset heart failure of uncertain etiology

The PROMISE trial (N=10,003) compared CCTA versus functional stress testing in stable outpatients and found no difference in composite cardiovascular events at 25 months, though CCTA led to more downstream catheterizations [14]. The SCOT-HEART trial, with longer follow-up, showed the outcomes benefit that PROMISE's shorter follow-up period missed [3].

CCTA is less useful in patients with extensive prior coronary stenting (metal artifact degrades image quality), very high heart rates that cannot be controlled with beta-blockers, or severe renal insufficiency (contrast risk). For these patients, stress MRI or invasive angiography may be more appropriate.

Dr. Matthew Budoff, a professor of medicine at the Lundquist Institute and one of the principal MESA investigators, has stated: "The calcium score is the strongest predictor of cardiac events we have. When it's zero, your short-term risk is extraordinarily low regardless of your Framingham score." [6]

Reading Your CCTA Report: A Practical Checklist

When you receive your CCTA results, look for these specific items in the report. If any are missing, ask your ordering clinician to clarify:

1. CAD-RADS classification (0-5): Your overall stenosis category
2. Plaque burden modifier (P1-P4, if using CAD-RADS 2.0): Total plaque volume assessment
3. CAC Agatston score: The numeric calcium burden
4. CAC percentile for age/sex/ethnicity: Context for your score relative to your demographic group (available via the MESA CAC calculator) [6]
5. Plaque composition: Whether identified plaque is calcified, non-calcified, or mixed
6. High-risk plaque features: Positive remodeling, low-attenuation plaque, spotty calcification, napkin-ring sign
7. Non-coronary findings: CCTA also captures portions of the lungs, mediastinum, and upper abdomen

A report that states only "no significant stenosis" without commenting on plaque composition, burden, or high-risk features is incomplete by current standards. The difference between "no significant stenosis with diffuse non-calcified plaque" and "no stenosis, no plaque" is the difference between early atherosclerosis and a genuinely clean vascular tree.

CAC Score of Zero: How Long Does the "Warranty" Last?

A CAC score of 0 provides powerful negative predictive value, but it is not permanent. The CAC Consortium study (N=13,460 with baseline CAC of 0) found that 25% of initially CAC-0 patients developed detectable calcium over a median follow-up of 4.1 years [15]. Risk factors for conversion from 0 to >0 included age over 60, diabetes, smoking, hypertension, and LDL-C above 160 mg/dL.

Current expert consensus from the Society of Cardiovascular Computed Tomography suggests that repeat CAC screening is reasonable at 5-year intervals for patients with an initial score of 0 who have ongoing risk factors [8]. For patients with no traditional risk factors and a CAC of 0, the warranty period may extend to 10 years or longer.

This means "optimal" is not a one-time finding. It requires longitudinal confirmation.